Allogene Extends Cash Runway into Q1 2028, Prepares for Key Clinical Data Readouts in April & June

summarizeSummary

Allogene Therapeutics reported its Q4 and full-year 2025 financial results, extending its cash runway into Q1 2028 and highlighting upcoming interim data from its pivotal ALPHA3 trial in April and proof-of-concept data for ALLO-329 in June.

check_boxKey Events

• Cash Runway Extended into Q1 2028

  The company ended Q4 2025 with $258.3 million in cash, cash equivalents, and investments, extending its financial runway into the first quarter of 2028. This reflects disciplined expense management and opportunistic use of its ATM facility.

• Pivotal ALPHA3 Trial Interim Analysis in April 2026

  Allogene's lead program, cema-cel, is undergoing a pivotal, randomized Phase 2 ALPHA3 trial. An interim futility analysis, evaluating MRD clearance and early safety results, is planned for April 2026.

• ALLO-329 Autoimmune Data Expected in June 2026

  Initial proof-of-concept data from the Phase 1 RESOLUTION trial for ALLO-329, a dual CD19/CD70 CAR T therapy for autoimmune diseases, is expected in June 2026.

• Full Year 2025 Financial Results

  The company reported a net loss of $190.9 million, or $0.87 per share, for the full year ended December 31, 2025, a reduction from the prior year's net loss of $257.59 million.

auto_awesomeAnalysis

This filing provides a significant update for Allogene Therapeutics, primarily driven by the extension of its cash runway into the first quarter of 2028. This financial stability, supported by $258.3 million in cash, cash equivalents, and investments as of Q4 2025, substantially de-risks the company's operations and provides a solid foundation for its clinical programs. Furthermore, the company highlighted two critical near-term catalysts: an interim futility analysis for the pivotal Phase 2 ALPHA3 trial in April 2026 and proof-of-concept data for the ALLO-329 autoimmune program in June 2026. These clinical milestones represent major value inflection points, and their outcomes will be crucial for the company's future trajectory. Investors should closely monitor these upcoming data readouts.